Please login to the form below
lipodystrophy
This page shows the latest lipodystrophy news and features for those working in and with pharma, biotech and healthcare.
Daily Brief: European approvals for BMS' Opdivo, Aegerion's lipodystrophy treatment, Pfizer's biosimilar and Xeljanz
Patients with lipodystrophy have previously relied on lifestyle changes and medications, like insulin injections to manage the condition’s associated complications. ... Today’s milestone marks a significant change in the way lipodystrophy is treated.
Latest news
-
Safety issues dampen enthusiasm for Akcea's volanesorsen
The company is upbeat about the prospects for the drug, which is also being developed for familial partial lipodystrophy (FPL), another rare disease characterised by elevated triglyceride levels.
-
Isis renamed Ionis to sidestep militant association
is in trials for familial chylomicronaemia syndrome and familial partial lipodystrophy.
-
R&D productivity takes off
lipodystrophy - now divested to Aegerion Pharmaceuticals - has been set at an eye-watering $325, 000 a year.
-
Sharing good diabetes practice in the NHS
In this case the judges decided that the National Severe Insulin Resistance Service, a new national clinical service for patients with severe insulin resistance and/or lipodystrophy, was a worthy winner
-
Nexium windfall lifts AZ in third quarter
Meanwhile, AZ also said it is selling Myalept (metreleptin), an approved drug for generalised lipodystrophy, to Aegerion Pharmaceuticals.
More from news
Approximately 1 fully matching, plus 13 partially matching documents found.
Latest Intelligence
-
Choices, choices: the rapidly evolving HIV treatment landscape
Since the advent of ARVs, the life expectancy of HIV patients has increased to be on par with those unaffected; however, long-term side-effects associated with NRTIs include lipodystrophy, kidney
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- AZ strengthens Daiichi Sankyo partnership with new ADC deal
- New study identifies drugs that are safe to use in COVID-19 treatment
- AbbVie, Amgen and Takeda team up for joint COVID-19 trial
- How will the events and exhibitions industry change post-Coronavirus?
- AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies
- Eli Lilly begins COVID-19 prevention trial in nursing homes
- Porterhouse Medical Group joins imc group
- Biogen pays Denali $1bn upfront for Parkinson’s disease programme
- Tecentriq combo fails in advanced triple negative breast cancer
- Bristol-Myers Squibb’s revenues rise on Celgene acquisition
- Socially distanced strategising
- Artificial Intelligence in Digital Therapeutics
PMHub
claire@dovetailstrategies.com
About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...
Latest intelligence
- Virtual Engagement At Porterhouse: Reflections on the past few months
- A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
- July 2020: diversity and inclusion in clinical trials round-up
- COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
- Medical Device Clinical Trials 2020
- In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...
Quick links
Infographics
